EU/3/03/145

Table of contents

About

On 10 June 2003, orphan designation (EU/3/03/145) was granted by the European Commission to Eurogen Pharmaceuticals Limited, United Kingdom, for rubitecan for the treatment of pancreatic cancer.

Key facts

Active substance
Rubitecan
Disease / condition
Treatment of pancreatic cancer
Date of first decision
10/06/2003
Outcome
Positive
EU designation number
EU/3/03/145

Sponsor's contact details

Eurogen Pharmaceuticals Ltd
The Gloucestershire Innovation Centre
Southgate House
Southgate Street
Gloucester GL1 1UD
United Kingdom
Telephone: +44 (0)1452 563 026
Telefax: +44 (0)1452 563 028
E-mail: Ljohnson@eurogenpharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating